Journal of Alzheimer’s Disease & Parkinsonism
Dale E Bredesen, Kenneth Sharlin, David Jenkins, Miki Okuno, Wes Youngberg, Sharon Hausman Cohen, Anne Stefani, Ronald L Brown, Seth Conger, Craig Tanio, Ann Hathaway, Mikhail Kogan, David Hagedorn, Edwin Amos, Amylee Amos, Nathaniel Bergman, Carol Diamond, Jean Lawrence, Ilene Naomi Rusk, Patricia Henry and Mary Braud
The first examples of reversal of cognitive decline in Alzheimer’s disease and the pre-Alzheimer’s disease conditions MCI (Mild Cognitive Impairment) and SCI (Subjective Cognitive Impairment) have recently been published. These two publications described a total of 19 patients showing sustained subjective and objective improvement in cognition, using a comprehensive, precision medicine approach that involves determining the potential contributors to the cognitive decline (e.g., activation of the innate immune system by pathogens or intestinal permeability, reduction in trophic or hormonal support, specific toxin exposure, or other contributors), using a computer-based algorithm to determine subtype and then addressing each contributor using a personalized, targeted, multi-factorial approach dubbed ReCODE for reversal of cognitive decline.
An obvious criticism of the initial studies is the small number of patients reported. Therefore, we report here 100 patients, treated by several different physicians, with documented improvement in cognition, in some cases with documentation of improvement in electrophysiology or imaging, as well. This additional report provides further support for a randomized, controlled clinical trial of…